超声造影肝脏影像报告与数据系统分类标准在M类病变中的应用及进展

吴星霓; 唐少珊; 李想; 李梓楠

doi:10.3969/j.issn.1001-5256.2022.10.041

超声造影肝脏影像报告与数据系统分类标准在M类病变中的应用及进展

DOI: 10.3969/j.issn.1001-5256.2022.10.041

中国医科大学附属盛京医院超声科，沈阳 110004

基金项目:

辽宁省科学技术基金 (2021JH2/10300114)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：吴星霓负责选题，收集分析资料，撰写文章；李想、李梓楠参与选题，收集资料；唐少珊指导撰写文章，提供修改意见并最终定稿。

详细信息

通信作者:
唐少珊，tangss@sj-hospital.org

计量
- 文章访问数: 541
- HTML全文浏览量: 109
- PDF下载量: 32
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-08
- 录用日期: 2022-04-11
- 出版日期: 2022-10-20

Application and progress of the contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) in "M" lesions

Department of Ultrasound, Shengjing Hospital, China Medical University, Shenyang 110004, China

Research funding:

Liaoning Province Science and Technology Foundation Project (2021JH2/10300114)

More Information

Corresponding author: TANG Shaoshan, tangss@sj-hospital.org(ORCID: 0000-0002-6020-991X)

摘要

摘要: 肝细胞癌(HCC)和非HCC肝恶性肿瘤在发病机制、生物学行为等方面存在显著差异，超声造影肝脏影像报告与数据系统(CEUS LI-RADS)中M类的存在为两者鉴别提供了新思路。本文介绍了CEUS LI-RADS分类标准在M类病变中的诊断应用情况及进展，认为应用CEUS LI-RADS可以帮助鉴别HCC和非HCC恶性肿瘤，但未来仍需进一步的改进和完善。
- 肝肿瘤 /
- 超声造影 /
- 肝脏影像报告与数据系统 /
- 诊断
Abstract: Clinically, there are still substantial differences between hepatocellular carcinoma (HCC) and non-HCC liver malignancies in terms of risk factors, pathogenesis, biological behaviors, treatment selections, prognosis, and prevention measurement. The liver imaging reporting and data system (LI-RADS) M (LR-M) classification criteria in the contrast-enhanced ultrasound LI-RADS (CEUS LI-RADS) can help differentiate HCC from non-HCC malignancies. This review discussed and summarized recent advancements in differential diagnosis of HCC from non-HCC using the LR-M criteria and speculated future directions in the field, i.e., how CEUS LI-RADS distinguish HCC from intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma cholangiocarcinoma, and liver metastasized and benign tumors. It also discussed differences between CEUS LI-RADS and CT/MRI LI-RADS in diagnosis of liver neoplasms and Sonazoid^Ⓡ modified CEUS LI-RADS in differential diagnosis of HCC from non-HCC.
- Liver Neoplasms /
- Contrast Enhanced Ultrasound /
- Liver Imaging Reporting And Data System /
- Diagnosis

HTML全文

参考文献(36)

[1]	LIU ZC, LI ZX, ZHANG Y, et al. Interpretation on the report of Global Cancer Statistics 2020[J/CD]. J Multidiscip Cancer Manag(Electr Vers), 2021, 7(2): 1-13. DOI: 10.12151/JMCM.2021.02-01. 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J/CD]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13. DOI: 10.12151/JMCM.2021.02-01.
[2]	Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[3]	SAPISOCHIN G, FIDELMAN N, ROBERTS JP, et al. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma[J]. Liver Transpl, 2011, 17(8): 934-942. DOI: 10.1002/lt.22307.
[4]	MASSARWEH NN, EL-SERAG HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3): 1073274817729245. DOI: 10.1177/1073274817729245.
[5]	WILSON SR, BURNS PN, KONO Y. Contrast-enhanced ultrasound of focal liver masses: a success story[J]. Ultrasound Med Biol, 2020, 46(5): 1059-1070. DOI: 10.1016/j.ultrasmedbio.2019.12.021.
[6]	BARTOLOTTA TV, TERRANOVA MC, GAGLIARDO C, et al. CEUS LI-RADS: a pictorial review[J]. Insights Imaging, 2020, 11(1): 9. DOI: 10.1186/s13244-019-0819-2.
[7]	FOWLER KJ, POTRETZKE TA, HOPE TA, et al. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma[J]. Abdom Radiol (NY), 2018, 43(1): 149-157. DOI: 10.1007/s00261-017-1196-2.
[8]	HU YX, SHEN JX, HAN J, et al. Diagnosis of non-hepatocellular carcinoma malignancies in patients with risks for hepatocellular carcinoma: CEUS LI-RADS versus CT/MRI LI-RADS[J]. Front Oncol, 2021, 11: 641195. DOI: 10.3389/fonc.2021.641195.
[9]	ZHANG JL, GE H, WU WJ. Diagnostic value of contrast-enhanced LI-RADS classification criteria in hepatocellular carcinoma[J]. Chin J Gen Pract, 2021, 19(5): 833-837. DOI: 10.16766/j.cnki.issn.1674-4152.001929. 张家玲, 葛晖, 武文娟. 超声造影LI-RADS分类标准对肝细胞癌的诊断价值[J]. 中华全科医学, 2021, 19(5): 833-837. DOI: 10.16766/j.cnki.issn.1674-4152.001929.
[10]	HAN H, KONG WT, QIU YD, et al. Diagnostic value of liver imaging reporting and data system for hepatocellular carcinoma by contrast-enhanced ultrasound[J]. J Clin Ultrasound Med, 2017, 19(8): 505-509. DOI: 10.16245/j.cnki.issn1008-6978.2017.08.001. 韩浩, 孔文韬, 仇毓东, 等. LI-RADS超声造影分类标准对肝细胞癌的诊断价值[J]. 临床超声医学杂志, 2017, 19(8): 505-509. DOI: 10.16245/j.cnki.issn1008-6978.2017.08.001.
[11]	ZHENG W, LI Q, ZOU XB, et al. Evaluation of contrast-enhanced US LI-RADS version 2017: application on 2020 liver nodules in patients with hepatitis B infection[J]. Radiology, 2020, 294(2): 299-307. DOI: 10.1148/radiol.2019190878.
[12]	DING JM, QIN ZY, WANG F. Development and clinical application of contrast enhanced ultrasound liver imaging reporting and data system[J]. J Clin Hepatol, 2022, 38(2): 466-470. DOI: 10.3969/j.issn.1001-5256.2022.02.043. 丁建民, 秦正义, 王芳. 超声造影肝脏影像报告和数据管理系统发展现状及临床应用进展[J]. 临床肝胆病杂志, 2022, 38(2): 466-470. DOI: 10.3969/j.issn.1001-5256.2022.02.043.
[13]	LI F, LI Q, LIU Y, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017[J]. Eur Radiol, 2020, 30(1): 461-470. DOI: 10.1007/s00330-019-06317-2.
[14]	CHEN LD, RUAN SM, LIANG JY, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound[J]. World J Gastroenterol, 2018, 24(33): 3786-3798. DOI: 10.3748/wjg.v24.i33.3786.
[15]	CHEN LD, RUAN SM, LIN Y, et al. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS[J]. Eur Radiol, 2019, 29(8): 4249-4257. DOI: 10.1007/s00330-018-5927-8.
[16]	SHIN J, LEE S, BAE H, et al. Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: A meta-analysis[J]. Liver Int, 2020, 40(10): 2345-2352. DOI: 10.1111/liv.14617.
[17]	LI J, YANG L, MA L, et al. Diagnostic accuracy of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) for differentiating between hepatocellular carcinoma and other hepatic malignancies in high-risk patients: a meta-analysis[J]. Ultraschall Med, 2021, 42(2): 187-193. DOI: 10.1055/a-1309-1568.
[18]	ZHAO ZL, TANG SS, PENG SS, et al. The diagnostic value of the LI-RADS classification of contrast-enhanced ultrasound in small hepatocellular carcinoma[J]. J China Med Univ, 2021, 50(7): 641-645. DOI: 10.12007/j.issn.0258-4646.2021.07.014. 赵子路, 唐少珊, 彭珊珊, 等. 超声造影LI-RADS分类在小肝癌诊断中的应用价值[J]. 中国医科大学学报, 2021, 50(7): 641-645. DOI: 10.12007/j.issn.0258-4646.2021.07.014.
[19]	LIU GJ, WANG W, LU MD, et al. Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Liver Cancer, 2015, 4(4): 241-252. DOI: 10.1159/000367738.
[20]	HUANG JY, LI JW, LING WW, et al. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?[J]. World J Gastroenterol, 2020, 26(27): 3938-3951. DOI: 10.3748/wjg.v26.i27.3938.
[21]	YANG J, ZHANG YH, LI JW, et al. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. World J Gastroenterol, 2020, 26(46): 7325-7337. DOI: 10.3748/wjg.v26.i46.7325.
[22]	LI R, YANG D, TANG CL, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography[J]. BMC Cancer, 2016, 16: 158. DOI: 10.1186/s12885-016-2156-x.
[23]	HUANG XW, HUANG Y, CHEN LD, et al. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma[J]. J Med Ultrason (2001), 2018, 45(2): 231-241. DOI: 10.1007/s10396-017-0834-1.
[24]	QUAIA E, GENNARI AG. The most appropriate time delay after microbubble contrast agent intravenous injection to maximize liver metastasis conspicuity on contrast-enhanced ultrasound[J]. J Med Ultrasound, 2018, 26(3): 128-133. DOI: 10.4103/JMU.JMU_12_17.
[25]	CAO DM, JING XX, LIN YW. Enhancement pattern of liver metastasis in contrast-enhanced ultrasonography: An analysis of 76 casess[J]. J Pract Hepatol, 2020, 23(3): 431-434. DOI: 10.3969/j.issn.1672-5069.2020.03.032. 曹东明, 景香香, 林运旺. 肝转移癌超声造影增强模式表现分析[J]. 实用肝脏病杂志, 2020, 23(3): 431-434. DOI: 10.3969/j.issn.1672-5069.2020.03.032.
[26]	DONG Y, ZHANG XL, MAO F, et al. Contrast-enhanced ultrasound features of histologically proven small (≤ 20 mm) liver metastases[J]. Scand J Gastroenterol, 2017, 52(1): 23-28. DOI: 10.1080/00365521.2016.1224380.
[27]	LIU X, NE NA, YE XJ, et al. Application of contrast-enhanced ultrasound in differential diagnosis of hepatocellular carcinoma and liver metastases[J]. J Pract Hepatol, 2020, 23(1): 94-97. DOI: 10.3969/j.issn.1672-5069.2020.01.026. 刘潇, 何年安, 叶显俊, 等. 超声造影对肝细胞癌与肝转移癌的鉴别诊断价值分析[J]. 实用肝脏病杂志, 2020, 23(1): 94-97. DOI: 10.3969/j.issn.1672-5069.2020.01.026.
[28]	FENG J, CHANG FL. Application of LI-RADS classification criteria in the identification and diagnosis of hepatocellular carcinoma[J]. Chin Hepatol, 2020, 25(3): 297-299. DOI: 10.3969/j.issn.1008-1704.2020.03.021. 冯俊, 常凤玲. 超声造影LI-RADS分类标准在肝细胞癌鉴别及诊断中的应用[J]. 肝脏, 2020, 25(3): 297-299. DOI: 10.3969/j.issn.1008-1704.2020.03.021.
[29]	ZHANG X, TANG S, HUANG L, et al. Contrast-enhanced sonographic characteristics of hepatic inflammatory pseudotumors[J]. J Ultrasound Med, 2016, 35(9): 2039-2047. DOI: 10.7863/ultra.15.10057.
[30]	XIA W, ZHANG WH. Research progress in diagnosis and treatment of pyogenic liver abscess[J]. Med Recapitulate, 2021, 27(13): 2630-2634. DOI: 10.3969/j.issn.1006-2084.2021.13.023. 夏伟, 张伟辉. 细菌性肝脓肿的诊疗研究进展[J]. 医学综述, 2021, 27(13): 2630-2634. DOI: 10.3969/j.issn.1006-2084.2021.13.023.
[31]	FU XB, CHEN JY. Application value of contrast-enhanced ultrasound in the diagnosis of hepatic abscess[J]. Chin Pract Med, 2018, 13(35): 23-24. DOI: 10.14163/j.cnki.11-5547/r.2018.35.010. 付小兵, 陈纪昀. 超声造影对肝脓肿诊断的应用价值[J]. 中国实用医药, 2018, 13(35): 23-24. DOI: 10.14163/j.cnki.11-5547/r.2018.35.010.
[32]	CARAIANI C, BOCA B, BURA V, et al. CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-can things be put together?[J]. Biology (Basel), 2021, 10(5): 412. DOI: 10.3390/biology10050412.
[33]	DING J, LONG L, ZHANG X, et al. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS[J]. Eur Radiol, 2021, 31(2): 847-854. DOI: 10.1007/s00330-020-07159-z.
[34]	LI L, HU Y, HAN J, et al. Clinical application of liver imaging reporting and data system for characterizing liver neoplasms: a meta-analysis[J]. Diagnostics (Basel), 2021, 11(2): 323. DOI: 10.3390/diagnostics11020323.
[35]	DIETRICH CF, AVERKIOU M, NIELSEN MB, et al. How to perform contrast-enhanced ultrasound (CEUS)[J]. Ultrasound Int Open, 2018, 4(1): E2-E15. DOI: 10.1055/s-0043-123931.
[36]	SUGIMOTO K, KAKEGAWA T, TAKAHASHI H, et al. Usefulness of modified CEUS LI-RADS for the diagnosis of hepatocellular carcinoma using sonazoid[J]. Diagnostics (Basel), 2020, 10(10): 828. DOI: 10.3390/diagnostics10100828.